Popular Articles
Stretch Mark Remedies

Varian Medical Systems Acquires Assets Of IKOEmed And IKOEtech; Acquisition To Add Software For Accelerating Radiotherapy Treatment Planning
Varian Medical Systems, Inc., (NYSE: VAR) announced it has acquired the assets of Houston-based IKOEmed and IKOEtech, privately-owned suppliers of software used in the planning of radiotherapy and radiosurgery treatments. The acquisition enables Varian to offer hospitals and clinics an additional software tool to automate and accelerate the most time-consuming portion of the treatment planning process. Varian is paying approximately $2.2 million plus an additional amount based on achievement of specified milestones to acquire the IKOE assets.
generic viagra online
3 Studies Confirm The Value Of Etanercept Therapy In Treating Juvenile Idiopathic Arthritis
Three new studies have individually shown the anti-TNF (tumour necrosis factor) therapy etanercept to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis (JIA), and associated with improved Health-Related Quality of Life (HRQoL) in a substantial proportion of children with JIA. The data are being presented at the Paediatric Rheumatology European Society Congress (PReS) 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
News of the day
Data Published In The New England Journal Of Medicine Support Use Of Raxibacumab (ABthrax(TM)) For The Treatment Of Inhalation Anthrax
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company"s human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease.
Public Health

ASGT 12th Annual Meeting: Incorporate Gene Therapy To Make Stem Cell Treatment Safer, More Effective

Gene therapy should be used in tandem with stem cell therapy to enhance the reliability of stem cells, provide an opportunity to limit adverse effects and increase treatment success, according to research presented at the American Society of Gene Therapy"s 12th Annual Meeting, May 30. "Stem cell therapy offers enormous potential to treat and even cure serious diseases. But wayward stem cells can turn into a runaway train without a conductor," said Ronald G. Crystal, MD, chief of the Division of Pulmonary and Critical Care Medicine at New York Presbyterian Hospital/Weill Cornell Medical Center. "This is an issue that can be dealt with and we have the technology to do that in the form of gene therapy." The challenges with stem cells are unique - once a transplant is performed, the cells go to work on their own, leaving the therapist without control of the therapy"s outcome. Gene therapy, however, provides a means for predetermining, and controlling, how the implanted stem cells will react in the patient. After implantation, stem cells multiply and differentiate into new types of cells. This ability is what gives them their unique potential as medical treatment. But problems arise when the cells differentiate incorrectly, multiply excessively, migrate to new areas of the body or form tumors. By modifying the genetic code of these cells prior to transplantation, researchers can program the cells to prevent adverse effects or self-destruct should they go awry. A couple of recent events have cast a new urgency on this research. In January, the Food and Drug Administration approved the first human trials using embryonic stem cells and, in March, the Obama administration reversed an earlier policy restricting federal funding for embryonic stem cell research. Scientists believe these steps will lead to accelerated development of stem cell therapies. Stem cells hold promise for treating a host of common diseases, including diabetes, Parkinson"s disease, cancer and others. The American Society of Gene Therapy (ASGT) 12th Annual Meeting is the world"s largest scientific meeting surrounding the latest developments in gene and cell therapy, attended by nearly 2,000 researchers from around the world and featuring 60 scientific presentations. ASGT


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):